Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, March 25, 2026. Management will host a webcast/teleconference at 4:30 p.m. ET the same day to discuss results and provide a corporate update.
Domestic dial-in is 1-800-717-1738, international dial-in is 1-646-307-1865, and a live webcast is available via the company link; a replay will be posted on Celcuity's website.
Positive
- None.
Negative
- None.
News Market Reaction – CELC
In the Mar 18 session, CELC declined 1.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 scheduling | Neutral | +2.2% | Announced Q3 2025 results release date and post-close webcast details. |
| Aug 07 | Q2 2025 scheduling | Neutral | +0.1% | Set date and access details for Q2 2025 results and webcast. |
| May 07 | Q1 2025 scheduling | Neutral | +0.6% | Outlined timing and dial-in for Q1 2025 financial results call. |
| Mar 24 | FY 2024 scheduling | Neutral | +3.2% | Announced Q4 and full-year 2024 release with same-day webcast. |
| Nov 07 | Q3 2024 scheduling | Neutral | -3.2% | Scheduled Q3 2024 results release and webcast timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings/webcast dates has historically led to modest single-day moves, ranging from about -3.2% to +3.24% around similar announcements.
Over the past year, Celcuity has regularly issued releases scheduling quarter and year-end results with associated webcasts at 4:30 p.m. ET. These “conferences, earnings” notices for Q3 2024, Q4 2024, and the 2025 quarterly results typically outlined post-close releases and standard dial-in details. Price reactions spanned small gains and losses around these routine updates. Today’s announcement continues that pattern by setting timing for Q4 and full year 2025 results and a same-day webcast and conference call.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1751140&tp_key=9ff20687c4. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has completed enrollment, and the company has reported detailed results for the PIK3CA wild-type cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine resistant HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
